CTAG1B and soft tissue sarcoma: Additionally, in a clinical trial (NCT04318964) investigating TCR-T cell therapy targeting CTAG1B, an ORR of 41.7% was observed across breast, liver, ovarian, and soft tissue sarcoma cancers.